Results 91 to 100 of about 2,075,366 (204)

SGLT2 inhibitors for the prevention and treatment of heart failure: A scientific statement of the HFA and the HFAI

ESC Heart Failure, Volume 12, Issue 6, Page 3806-3825, December 2025.
Abstract In the 2021 European Society of Cardiology (ESC) heart failure (HF) guidelines, sodium–glucose cotransporter 2 (SGLT2) inhibitors were recommended for the prevention of HF in patients with type 2 diabetes mellitus (T2DM) and for the treatment of HF with reduced ejection fraction (HFrEF).
Marco Metra, Daniela Tomasoni, Marianna Adamo, Offer Amir, Stefan D. Anker, Antoni Bayes‐Genis, Michael Boehm, Javed Butler, Ovidiu Chioncel, Gerasimos Filippatos, Finn Gustafsson, Ewa A. Jankowska, Juan Carlos Kaski, Brenda Moura, Mark C. Petrie, Piotr Ponikowski, Amina Rakisheva, Arsen Ristic, Francois Roubille, Gianluigi Savarese, Petar Seferovic, Peter van der Meer, Maurizio Volterrani, Andrew J. Coats, Vijay K. Chopra, Giuseppe Rosano   +25 more
wiley   +1 more source

A new staging system for hereditary transthyretin amyloidosis in the era of specific amyloidosis therapies

ESC Heart Failure, Volume 12, Issue 6, Page 4125-4139, December 2025.
The aim of our study was to develop a more accurate staging system for hereditary ATTR patients currently receiving specific treatment. A staging system was created using as criteria: GLS ≤ −11%, NT‐proBNP ≤ 2,000 ng/L, and eGFR ≤ 65 mL/min. We managed to accurately stratify patients into three disease stages, significantly different in terms of ...
Gabriela Neculae, Amira Zaroui, Robert Adam, Mounira Kharoubi, Benoit Funalot, Daniel Coriu, Ruxandra Jurcut, Thibaud Damy   +7 more
wiley   +1 more source

Incidence and Predictors of Right Ventricular Reverse Remodeling in Patients with Transthyretin Amyloid Cardiomyopathy Treated with Tafamidis

Biomedicines
Background/Objectives: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), the effect of tafamidis on right ventricular (RV) dysfunction has been poorly investigated.
Nicoleta Nita, Dominik Felbel, Michael Paukovitsch, Felix von Sanden, Elene Walter, Rima Melnic, Wolfgang Rottbauer, Dominik Buckert, Johannes Mörike   +8 more
doaj   +1 more source

Emerging Role of Scintigraphy Using Bone-Seeking Tracers for Diagnosis of Cardiac Amyloidosis:AJR Expert Panel Narrative Review [PDF]

Amyloidoses are a complex group of clinical diseases that result from progressive organ dysfunction due to extracellular protein misfolding and deposition.
Chareonthaitawee, Panithaya, Chen, Wengen, Davies, Daniel R., Grogan, Martha, Kittleson, Michelle M., Slart, Riemer H.J.A., Slomka, Piotr J., Thomson, Louise E.J., Tingen, Hendrea S.A., Tubben, Alwin, Wechalekar, Ashutosh D., Wechalekar, Kshama   +11 more
core   +1 more source

Effect of Tafamidis on Cardiac Function in Patients With Transthyretin Amyloid Cardiomyopathy: A Post Hoc Analysis of the ATTR-ACT Randomized Clinical Trial [PDF]

, 2023
IMPORTANCE: Tafamidis has been shown to improve survival in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with placebo. However, its effect on cardiac function has not been fully characterized.
Boman, Kurt, Elliott, Perry, Fernandes, Fabio, Fine, Nowell, Garcia-Pavia, Pablo, Gundapaneni, Balarama, Klein, Allan L, Maurer, Mathew S, Shah, Sanjiv J, Sultan, Marla B, Weissman, Neil J   +10 more
core  

When to suspect and how to approach a diagnosis of amyloidosis [PDF]

, 2022
Diagnoses of amyloidosis, particularly transthyretin amyloid cardiomyopathy (ATTR-CM), are steadily increasing throughout the world but the condition remains underdiagnosed.
Gillmore, Julian D, Law, Steven
core  

Clinical and Prognostic Implications of Right Ventricular Uptake on Bone Scintigraphy in Transthyretin Amyloid Cardiomyopathy [PDF]

Background: The extent of myocardial bone tracer uptake with technetium pyrophosphate, hydroxymethylene diphosphonate, and 3,3-diphosphono-1,2-propanodicarboxylate in transthyretin amyloid cardiomyopathy (ATTR-CM) might reflect cardiac amyloid burden and
Alberto Miceli, Aldostefano Porcari, Andrea Paccagnella, Angelo Giuseppe Caponetti, Anna Lisa Martini, Christian Gagliardi, Claudio Rapezzi, David F. Hutt, Dorota Rowczenio, Egidio Natalino Costanzo, Elena Biagini, Federico Perfetto, Franca Dore, Francesca Girardi, Francesco Cappelli, Giacomo Tini, Gianfranco Sinagra, Giovanni La Malfa, Giulia Barbati, Janet Gilbertson, Julian D. Gillmore, Linda Pagura, Marco Canepa, Marco Merlo, Marianna Fontana, Matteo Bauckneht, Mattia Zampieri, Maurizio Sguazzotti, Philip N. Hawkins, Rachele Bonfiglioli, Roberto Sciagrà, Simone Longhi   +31 more
core   +5 more sources

Cardiac Resynchronization Therapy, Remodeling, and Outcome in Patients With Amyloid Transthyretin Cardiomyopathy

Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease
Background Transthyretin amyloid cardiomyopathy (ATTR‐CM) has a specific pathophysiology, with myocardial stiffening and systolic dysfunction only in advanced stages. We aimed to investigate the response to cardiac resynchronization therapy (CRT) in ATTR‐
Alberto Aimo, Martina Nesti, Giuseppe Vergaro, Ammar M. Killu, Dimitrios Bampatsias, Daniela Tomasoni, Cinzia Forleo, Francesco Musca, Matteo Serenelli, Julie Rosenthal, Sergio L. Teruya, Nader J. Al‐Shakarchi, Mariel S. Tameze, Vincenzo Castiglione, Alessio Nicolai, Giorgia Panichella, Riccardo Saro, Aldostefano Porcari, Giulio Sinigiani, Vera Fico, Elisa Frau, Reem Matar, Andrea I. Guaricci, Giacomo Tini, Alberto Cipriani, Maria B. Musumeci, Simone Longhi, Cristina Chimenti, Marco Metra, Martha Grogan, Federico Perfetto, Francesco Cappelli, Marco Merlo, Gianfranco Sinagra, Mathew S. Maurer, Ahmad Masri, Michele Emdin   +36 more
doaj   +1 more source

Best Practices for Prognostic Evaluation of a Patient With Transthyretin Amyloid Cardiomyopathy

JACC. CardioOncology, 2019
Transthyretin amyloid cardiomyopathy (ATTR-CM) has emerged as an increasingly identified etiology of heart failure. Fortunately, the disease now has an approved therapy, with many others under development.
Kent Y. Feng, MD, Rahul S. Loungani, MD, Vishal N. Rao, MD, MPH, Chetan B. Patel, MD, Michel G. Khouri, MD, G. Michael Felker, MD, MHS, Adam D. DeVore, MD, MHS   +6 more
doaj   +1 more source

Deep phenotyping of p.(V142I)‐associated variant transthyretin amyloid cardiomyopathy: Distinct from wild‐type transthyretin amyloidosis? [PDF]

Aims: Transthyretin amyloid cardiomyopathy (ATTR-CM) is an increasingly recognized cause of heart failure. A total of 3-4% of individuals of African descent carry a TTR gene mutation encoding the p.(V142I) variant, a powerful risk factor for development ...
Blakeney, Iona, Bolhuis, Roos Eline, Chacko, Liza, Coghlan, John G., Filisetti, Stefano, Fontana, Marianna, Ganesananthan, Sashiananthan, Gilbertson, Janet, Gillmore, Julian D., Hawkins, Phillip, Hutt, David, Ioannou, Adam, Karia, Nina, Kaza, Nandita, Knight, Daniel S., Kotecha, Tushar, Lachmann, Helen J., Mahmood, Shameem, Martinez‐Naharro, Ana, Patel, Rishi K., Petrie, Aviva, Porcari, Aldostefano, Rauf, Muhammad Umaid, Razvi, Yousuf, Riefolo, Mattia, Rowczenio, Dorota, Starr, Neasa, Venneri, Lucia, Wechalekar, Ashutosh D., Whelan, Carol J.   +29 more
core   +1 more source